{"filings":[{"id":113912,"accession_number":"0001493152-26-009699","cik":715446,"company_name":"Anixa Biosciences Inc","ticker":"ANIX","form_type":"8-K","filed_at":"2026-03-11T23:59:59+00:00","items":["5.07","7.01","9.01"],"status":"ready","headline":"Anixa holds annual meeting; re-elects four directors, approves say-on-pay and auditor ratification","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Re-elected Kumar, Baskies, Gottschalk, Titterton as directors; each received 7.2M+ votes for.","Non-binding advisory vote on executive compensation passed with 6.0M for, 3.0M against.","Ratified Haskell & White LLP as independent auditor for FY ending Oct 31, 2026.","Presentation used at meeting furnished as Exhibit 99.1 but no text provided in filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":88848826.28205128,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113911,"accession_number":"0001493152-26-005702","cik":715446,"company_name":"Anixa Biosciences Inc","ticker":"ANIX","form_type":"8-K","filed_at":"2026-02-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Anixa reports extended survival in ovarian cancer CAR-T trial; regulatory approval for 100x dose escalation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["12 patients treated; 7 lived beyond expected median survival of 3-4 months; one survived 28 months.","No dose-limiting toxicities; protocol amended to escalate from 1x10^7 to up to 1x10^9 cells/kg (100x increase).","Next cohort includes lymphodepletion to potentially enhance CAR-T efficacy in solid tumors.","Three patients remain alive at 15, 14, and 8 months post-treatment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":88848826.28205128,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130319,"accession_number":"0001493152-25-027321","cik":715446,"company_name":"Anixa Biosciences Inc","ticker":"ANIX","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Anixa reports final Phase 1 breast cancer vaccine data: 74% immune response, safe, advancing to Phase 2","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Vaccine met all primary endpoints; 74% of participants showed protocol-defined aLA-specific T cell responses.","Well tolerated at max tolerated dose; main adverse event was injection-site irritation; no flu-like symptoms.","Combination with Keytruda generated T cell responses without major additional side effects.","Enrolled 35 participants across three cohorts: early-stage TNBC, preventive mastectomy, adjuvant Keytruda.","Planning Phase 2 neoadjuvant combination study with Keytruda in newly diagnosed breast cancer patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":88848826.28205128,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183010,"accession_number":"0001493152-25-011151","cik":715446,"company_name":"Anixa Biosciences Inc","ticker":"ANIX","form_type":"8-K","filed_at":"2025-03-21T23:59:59+00:00","items":["5.07","7.01","9.01"],"status":"ready","headline":"Anixa Biosciences annual meeting re-elects four directors, approves say-on-pay 66%-33%","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Dr. Amit Kumar, Dr. Arnold Baskies, Emily Gottschalk, Lewis Titterton re-elected as directors with 97-99% of votes cast.","Executive compensation approved on advisory basis: 6.6M for, 3.4M against (66% support).","Ratification of Haskell & White LLP as auditor for FY2025 passed with 19.9M for, 187k against.","Advisory vote on frequency of future say-on-pay: one-year option received 8.7M votes vs 1.1M for three years.","Broker non-votes totalled 10.5M shares on director elections and compensation proposals (32.7% of outstanding)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":88848826.28205128,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199584,"accession_number":"0001493152-24-044224","cik":715446,"company_name":"Anixa Biosciences Inc","ticker":"ANIX","form_type":"8-K","filed_at":"2024-11-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Anixa Biosciences presents updated positive Phase 1 data for breast cancer vaccine; Phase 2 planned for 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1 trial of alpha-lactalbumin vaccine updated at SITC; data continue positive trend across 3 cohorts.","Vaccine safe and well tolerated; only notable side effect was injection-site irritation.","Over 70% of patients exhibited protocol-defined immune responses (interferon-gamma, interleukin-17).","Combination with Keytruda (Cohort 1c) showed no major adverse events; one Grade 3 injection-site reaction in a recently lactated patient.","Phase 2 neoadjuvant study with randomized control planned to commence in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":88848826.28205128,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":234980,"accession_number":"0001493152-24-018170","cik":715446,"company_name":"Anixa Biosciences Inc","ticker":"ANIX","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Anixa expands Cleveland Clinic joint development to develop additional cancer vaccines","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Anixa and Cleveland Clinic entered Joint Development and Option Agreement to develop vaccines for multiple cancers.","Anixa to pay non-refundable option fee and development funding in three tranches; first due May 8, 2024.","Option to obtain exclusive, royalty-bearing worldwide license to inventions developed under agreement.","Builds on existing breast cancer (Phase 1 TNBC) and ovarian cancer vaccine programs with Cleveland Clinic.","Research led by Dr. Thaddeus Stappenbeck and Dr. Justin Johnson at Cleveland Clinic."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":88848826.28205128,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":252810,"accession_number":"0001493152-24-010995","cik":715446,"company_name":"Anixa Biosciences Inc","ticker":"ANIX","form_type":"8-K","filed_at":"2024-03-22T23:59:59+00:00","items":["5.07","7.01","9.01"],"status":"ready","headline":"Anixa Biosciences re-elects four directors and ratifies auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dr. Amit Kumar, Dr. Arnold Baskies, Emily Gottschalk, and Lewis H. Titterton, Jr. re-elected as directors with 7.9M-7.7M votes for.","Executive compensation approved on non-binding advisory basis: 6.0M for, 1.8M against, 123K abstain.","Haskell & White LLP ratified as independent auditor for FY ending Oct 31, 2024: 18.4M for, 80K against, 51K abstain.","Total shares present at meeting: 18,521,786 out of 31,711,753 eligible shares (58.4% turnout)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":88848826.28205128,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}